LivaNova PLC

LIVN: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
pHzLOCK|@#DYLLOCK|xk

Livanova Earnings: Strength in 2025 Leaves Firm Poised for Favorable 2026

Livanova reported revenue growth of 10% (in constant currency) for both the fourth quarter and full-year 2025. This was fueled by 13% and 7% increases in cardiopulmonary and neuromodulation revenue in 2025, respectively.

Sponsor Center